Health & Wellness

Patents, Patients and Patience

  • Edge Editorial Team

    At Edge Investments, we make investing in small cap stocks enjoyable and edge-ucational. We are here to teach you about investing, keep you up to date on news, and help connect you with companies that you may have a desire to invest in.

    View all posts

[fusion_builder_container type=”flex” hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=””][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” first=”true”][fusion_text]As you know, NeonMind has been on our radar lately, and its no surprise why. With a rapidly progressing industry and the company’s diversification of revenue streams, we’re becoming more bullish on the potential for explosive growth by the day.  

A few highlights to date: 

  • Appointing well-known Trevor Millar as Chief Psychedelic Officer, long-time advocate of psychedelic science as a treatment for addiction, who has been on the Board of Directors for the Multidisciplinary Association of Psychedelic Studies (MAPS) for multiple years. MAPS is one of the global leaders in psychedelic research, and they have historically raised $110M for investigation and lobbying on the topic. 
  • NeonMind filed four applications on February 2, 2021 to Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD), with the intention to obtain product licenses for its 100% plant-based extracts to be able to make coveted health claims. 
  • The company welcomed Rob Tessarolo as Chief Executive Officer: former President & CEO of Mind Medicine ($MMED) and 25-year pharmaceutical industry veteran. 

And most recently, NeonMind has Engaged pharma executive, Philippe Martin, to advance its psilocybin drug candidates for obesity. Martin comes with 20 years of biotechnology and pharmaceutical industry experience, developing and commercializing innovative therapies in the fields of immunology, oncology, and neurology. Martin’s primary role is to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind’s two psilocybin drug development programs. 

Martin’s most recent venture took the form of Chief of Clinical Development & Operations at BioAtla, Inc. ($BCAB), a San Diego-based biotech company that develops novel therapies with improved therapeutic index, which have the potential to revolutionize cancer treatment. 

As the journey unfolds, we’re pleased to update you even further on what’s been on $NEON’s mind.

See what we did there? 

Patents. 

NeonMind has been strategically applying for patents since 2019, when the company filed its first U.S. provisional patent. With the help of data from initial first clinical trials in November of 2020, they have not only filed 9 other patents, but have converted 2 of their patent applications into Patent Cooperation Treaty (PCT) applications.  This kind of application means the intellectual ownership of the technology they are claiming will stand strong across 152 countries 

Exclusivity in your own country is one thing, let alone over 75% of the globe. 

With a huge majority of Neon’s focus in treating various eating disorders through the administration of psilocybin, NeonMind is starting to position itself to take the full lead in this division of the market. The weight management market, in particular, does not receive nearly the amount of attention it deserves, according to CEO Robert Tessarolo. 

“Through an expanded portfolio of patent applications, NeonMind is uniquely positioned to pursue exciting drug development opportunities in the enormously underserved weight management market. There have been so many solutions developed in the past that have disappointed; a new approach is desperately needed. We are actively building out our capabilities to execute the critical phases of drug development needed to support new drug applications to the FDA,” chimes the former Mindmed CEO. 

To summarize the numbers, NeonMind holds 10 U.S. provisional patents, 2 of which are converted to PCT’s to acquire potential rights in 152 countries, covering 7 areas of focus regarding treatment. 

The treatments included in NeonMind’s patent portfolio are as follows: 

  • Aiding weight loss, 
  • Obesity, 
  • Compulsive eating disorder, 
  • Diet alteration,
  • Reduction of food cravings, 
  • Decreasing food intake, and 
  • Complications associated with obesity. 

All of the intellectual property is 100% owned by NeonMind, except for the patents regarding LSD, LSA, and DMT; 20% of the rights for these patents belong to research collaborator Translational Life Sciences Inc. 

Patients. 

As we know, conditions such as eating disorders are much more than just an amplified appetite for snacks; they derive from behavioral issues in the brain, often stemming from a type of physiological trauma. Such is the reason why treatments such as cognitive therapy are needed for patients who are not only undergoing, but completed weight loss treatment. NeonMind is here to assist such cognitive therapy with the assistance of psychedelics.

After all, if you suffer from an eating disorder (whether it’sobesity,anorexia, or anything in between), simply recovering back to a healthy weight is not the end of the journey. To truly be free of a disorder like that, attention needs to be directed to the root of the problem, within the patient’s mind. 

Enter Cretara. 

Cretara is a scientific team that holds more than 3,500 years of collective drug discovery and development experience. They enhance the typical biopharmaceutical R&D process with bio simulation software. In the last 7 years, 90% of new drug and biologic approvals by the FDA have been successfully received by Certara’s customers. 

NeonMind’s R&D efforts are explored in a variety of ways, regarding their innovative approach so support and treat weight loss. Between 2 candidates, one of them will take a low dose of synthetic psilocybin as a treatment to suppress appetite. The other will take the synthetic psilocybin in an effort to enhance the patient’s ability to alter the behaviors that led to the eating disorder, in the first place. This covers both the surface symptom and root cause of these conditions, showcasing the versatility of psilocybin in relation to treatment. 

Cretara provides invaluable, worldclass R&D expertise to spearhead these trials and candidate studies. Their extensive network and technology enhance Neon’s drug development process in aiding weight loss treatment globally, painting a healthy picture for the patients of the future. 

Patience 

After all, executing the synthetic development of a recently decriminalized substance for medical purposes, while also undergoing several clinical trials to treat weight-related conditions (that cripple nearly half the population of the U.S.)… is no small feat. However, let’s not forget that NeonMind is effectively creating a revenue stream in the meantime through their nutritional blends of superfood coffees, utilizing the mental and physical benefits of functional mushrooms. Not only does this float the company as they rigorously develop their clinical arm, but it also reduced the need for any further financings. 

Being long on this company is akin to being long on the treatment of people worldwide, suffering from problems that the current medical system has yet to properly solve.  

For that, we have patience. 

Disclaimer: NeonMind Biosciences is a communications client of Edge Investments, and we own shares in the company.[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

  • Edge Editorial Team

    At Edge Investments, we make investing in small cap stocks enjoyable and edge-ucational. We are here to teach you about investing, keep you up to date on news, and help connect you with companies that you may have a desire to invest in.

    View all posts

Leave a Comment

Get 30+ hours of analyst research directly in your inbox weekly. Sign-up today to stay on top of the market.